Evidence map›Paper›PMID 25835195›Full record

ArticleGenetics in medicine : official journal of the American College of Medical Genetics2015

Key emerging themes for assessing the cost-effectiveness of reporting incidental findings.

Kathryn A Phillips, Uri Ladabaum, Mark J Pletcher, Deborah A Marshall, Michael P Douglas

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Genetics in medicine : official journal of the American College of Medical Genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Methodological Issues in Assessing the Economic Value of Next-Generation Sequencing Tests: Many Challenges and Not Enough Solutions.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2018
    Review
  2. "What Goes Around Comes Around": Lessons Learned from Economic Evaluations of Personalized Medicine Applied to Digital Medicine.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2017
    Article
  3. Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping review.Genetics in medicine : official journal of the American College of Medical Genetics · 2016
    Article
  4. Response to Phillips et al.Genetics in medicine : official journal of the American College of Medical Genetics · 2015
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Kathryn A PhillipsDepartment of Clinical Pharmacy, Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), Philip R. Lee Institute for Health Policy; and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.
Uri Ladabaum1] School of Medicine, Stanford University, Sanford, California, USA [2] Department of Clinical Pharmacy, Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), University of California San Francisco, San Francisco, California, USA.
Mark J Pletcher1] Department of Clinical Pharmacy, Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), University of California San Francisco, San Francisco, California, USA [2] Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
Deborah A Marshall1] Department of Clinical Pharmacy, Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), University of California San Francisco, San Francisco, California, USA [2] Department of Community Health Sciences, Cumming School of Medicine; O`Brien Institute for Public Health, University of Calgary, Calgary, Alberta, Canada.
Michael P DouglasDepartment of Clinical Pharmacy, Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), University of California San Francisco, San Francisco, California, USA.ORCID 0000000185176678

Funding

Risk-Benefit Trade-Offs for Whole Genome SequencingR01HG007063 · NHGRI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PHILLIPS, KATHRYN A · 2013 to 2016
$2.5M
NHGRI NIH HHS R01 HG007063
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

FemaleGenomicsHigh-Throughput Nucleotide SequencingHumansMale

Identifiers

PMID25835195
PMCPMC4395812

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.